In this study, the nanocomposite adsorbent (ZnS-zeolite NaA) was prepared by a simple ion-exchange method, which modified the zeolite NaA synthesized from fly ash. The removal efficiency, adsorption mechanism of mercury ions by ZnS-zeolite NaA and release of zinc ion into aqueous solution during the adsorption process were determined. The results showed that ZnS nanoclusters were introduced the supercages of zeolite by ion exchange to synthesize the ZnS-zeolite NaA with high removal capacity for Hg2+ in the initial pH 2-7 of solution. Determination of the adsorption kinetics and thermodynamic parameters, in combination with X-ray diffraction, X-ray photoelectron spectroscopy and transmission electron microscopy analyses, revealed that the Hg2+ adsorption by ZnS-zeolite NaA was Hg2+ complexed and ion exchanged with ZnS in the ZnS-zeolite NaA to form stable HgS, and then, the released Zn2+ was adsorbed by the zeolite, preventing Zn2+ pollution. The Hg2+ removal rate was greater than 99.90% with the coexistence of either Zn2+ or Cu2+, Cd2+ and Pb2+. After five repetitions, the Hg2+ removal rate by the ZnS-zeolite NaA was only slightly decreased by 2%. Therefore, ZnS-zeolite NaA synthesized using fly ash has potential for broad application as a Hg2+ adsorbent.The molecular and physiological mechanisms of how rare earth oxide nanoparticles (NPs) alter radish (Raphanus sativus L.) taproot formation and cracking were investigated in the present study. We compared plants that received suspensions of 10, 50, 100, 300 mg L-1 of La2O3 NPs, 300 m L-1 La2O3 bulk-particles (BPs), 0.8 m L-1 La3+, or only water for six days during their tuber formation period. 100 and 300 mg L-1 La2O3 NPs exposure decreased storage root biomass by 38% and 60%, respectively, and they both induced visible root cracking. Physiological analyses showed that La2O3 NPs exposure (>100 mg L-1) significantly inhibited leaf net photosynthetic rate, cell wall pectin synthesis of both storage root epidermis and xylem parenchyma tissues, but increased the contents of cellulose and hemicellulose 1 in root epidermis cell walls. Moreover, transcriptome analysis further found that La2O3 NPs changed root cell wall structure by down-regulating core genes involved in cell wall pectin and IAA biosynthesis, which coincided with the observed La2O3 NPs-induced root cracking. Our results revealed the molecular mechanisms related to cell wall carbohydrate metabolism in response to NPs stress, providing a step forward for understanding the causes of NPs phytotoxicity on edible plant taproot formation and cracking.Both green tea (GT) extract and vitamin C (VC) were used for the reduction of Fe3+ to Fe0 using a green synthesis method. Modified nanozero-valent iron (GT-nZVI@VC nanocomposites) was successfully obtained and characterized as α-Fe0-iron oxide/VC by multiple analytical methods. The GT-nZVI@VC nanocomposites showed better transportability than nZVI, in that transport behavior was slightly dependent on various ratios of sand/soil in water-saturated heterogeneous porous media. Breakthrough curves of GT-nZVI@VC nanocomposites in paddy soil exhibited "blocking effects" and were well described using a first-order straining coefficient (k2) on site 2 obtained from a two-site kinetic attachment model. In particular, GT-nZVI@VC (VC/Fe = 0.6) showed higher Cr(VI) removal (especially reducibility) in both paddy soil and water compared to that of nZVI and VC. It is likely that the synergistic effects of VC (ascorbic acid) and tea polyphenols can increase the released free electrons into solution, favoring the high reduction of Cr(VI) into Cr(III) (i.e., FeOCr2O3, Cr(OH)3 and Cr2O3), where Cr(III) is prone to be immobilized by the nanocomposites in soil. This research highlights that VC can mediate the activation of GT extract to successfully modify nZVI, which could be beneficial for efficient transport in subsurface and remediation of Cr(VI)-contaminated soil and underground water. The purpose of the study was to examine the performance of Persian speaking children who stutter (CWS) and children who do not stutter (CWNS) on three nonword repetition tasks, while also focusing on which task and scoring method best differentiates the two groups of children. Thirty CWS and 30 CWNS between the ages of 5;0 to 6;6 completed three nonword repetition tasks that varied in complexity. Each task was scored using two methods nonwords correct and phonemes correct. https://www.selleckchem.com/products/Rapamycin.html Between-group differences in performance on each task were examined, along with disfluencies for CWS and the task and scoring method that best differentiated the CWS and CWNS. The findings revealed that, across all three nonword repetition tasks, the CWS consistently produced fewer nonwords correct and phonemes correct than the CWNS group at virtually all syllable lengths. The CWS produced more disfluencies on longer nonwords than shorter nonwords in all three nonword repetition tasks. The nonword repetition task with lower wordlikeness and more phonologically complex items best differentiated the two groups of children. Findings further revealed that discriminative accuracy was highest for scoring based on the number of phonemes produced correctly. Findings provide further evidence to suggest that CWS may have difficulty with phonological working memory and/or phonological processing. Findings provide further evidence to suggest that CWS may have difficulty with phonological working memory and/or phonological processing. . Teriflunomide is an immunomodulatory drug approved for Multiple Sclerosis (MS) treatment that inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in the de novo pyrimidine synthesis pathway. This mechanism can produce antiviral effects, thus teriflunomide has gained attention during COVID-19 pandemic. Moreover, in the last months, some case-reports have been published describing MS patients treated with teriflunomide who developed mild and self-limiting forms of COVID-19. Here, we describe the case of a 57-year-old man affected by MS, and treated with teriflunomide, who developed a mild form of SARS-CoV-2 infection. Moreover, we provide a detailed literature review about the available cases of COVID-19 in MS patients treated with teriflunomide. We report clinical features, disease course and outcome, and we discuss similarities and differences among patients. Apart from the present report, since February 2020, five papers have been published describing 14 MS patients who developed SARS-CoV-2 infection during teriflunomide treatment.